IN8bio, Inc. (INAB)
NASDAQ: INAB · IEX Real-Time Price · USD
1.020
-0.020 (-1.92%)
At close: May 2, 2024, 4:00 PM
1.030
+0.010 (0.98%)
After-hours: May 2, 2024, 5:22 PM EDT
IN8bio Employees
IN8bio had 31 employees on December 31, 2023. The number of employees increased by 5 or 19.23% compared to the previous year.
Employees
31
Change (1Y)
5
Growth (1Y)
19.23%
Revenue / Employee
n/a
Profits / Employee
-$967,968
Market Cap
44.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31 | 5 | 19.23% |
Dec 31, 2022 | 26 | 7 | 36.84% |
Dec 31, 2021 | 19 | 12 | 171.43% |
Sep 30, 2020 | 7 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
INAB News
- 2 days ago - IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma - GlobeNewsWire
- 8 days ago - IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - GlobeNewsWire
- 16 days ago - IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference - GlobeNewsWire
- 23 days ago - IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 - GlobeNewsWire
- 7 weeks ago - IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - IN8bio to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology - GlobeNewsWire